Journal: Diabetology & Metabolic Syndrome

Article Title: Klotho and SIRT1 changes from pre-diabetes to diabetes and pre-hypertension to hypertension

doi: 10.1186/s13098-021-00736-2

Figure Lengend Snippet: Box and whisker plot of serum Klotho levels among different groups. The boxes represent the 25th and 75th percentiles, and the central lines in the boxes represent the median values. Whiskers are presented as median ± 95% CI. CTL control; Pre-DM pre-diabetes; DM diabetes mellitus; Pre-HTN pre-hypertension; HTN hypertension. **P < 0.01 vs. CTL, $$ P < 0.01 vs. Pre-DM, ## P < 0.01 vs. Pre-HTN

Article Snippet: Serum levels of Klotho and SIRT1 were measured by ELISA method using Human Klotho ELISA kit (R&D Systems with coefficient of variation < 10%) and Human SIRT1 ELISA kit (Elab Science with coefficient of variation < 10%).

Techniques: Whisker Assay, Control

Journal: Diabetology & Metabolic Syndrome

Article Title: Klotho and SIRT1 changes from pre-diabetes to diabetes and pre-hypertension to hypertension

doi: 10.1186/s13098-021-00736-2

Figure Lengend Snippet: Correlations of serum levels of Klotho ( A , C , E ) or SIRT1 ( B , D , F ) with FBS over the normal/Pre-DM ( A , B ) or normal to DM range ( C – F ). C , D linear, and E , F quadratic versions. CTL control; Pre-DM pre-diabetes; DM diabetes mellitus; FBS fasting blood sugar

Article Snippet: Serum levels of Klotho and SIRT1 were measured by ELISA method using Human Klotho ELISA kit (R&D Systems with coefficient of variation < 10%) and Human SIRT1 ELISA kit (Elab Science with coefficient of variation < 10%).

Techniques: Control

Journal: Diabetology & Metabolic Syndrome

Article Title: Klotho and SIRT1 changes from pre-diabetes to diabetes and pre-hypertension to hypertension

doi: 10.1186/s13098-021-00736-2

Figure Lengend Snippet: Correlations of serum levels of Klotho ( A , C , E ) or SIRT1 ( B , D , F ) with MAP over the normal/Pre-HTN ( A , B ) or normal to HTN ( C – F ). C , D linear, and E , F quadratic versions. CTL control; Pre-HTN pre-hypertension; HTN hypertension; MAP mean arterial pressure

Article Snippet: Serum levels of Klotho and SIRT1 were measured by ELISA method using Human Klotho ELISA kit (R&D Systems with coefficient of variation < 10%) and Human SIRT1 ELISA kit (Elab Science with coefficient of variation < 10%).

Techniques: Control

Journal: Diabetology & Metabolic Syndrome

Article Title: Klotho and SIRT1 changes from pre-diabetes to diabetes and pre-hypertension to hypertension

doi: 10.1186/s13098-021-00736-2

Figure Lengend Snippet: Linear regression of serum Klotho or SIRT1 level, as dependent variables, with age, BMI, FBS, MAP in studied groups

Article Snippet: Serum levels of Klotho and SIRT1 were measured by ELISA method using Human Klotho ELISA kit (R&D Systems with coefficient of variation < 10%) and Human SIRT1 ELISA kit (Elab Science with coefficient of variation < 10%).

Techniques:

Journal: Cell death & disease

Article Title: FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling.

doi: 10.1038/s41419-021-03693-w

Figure Lengend Snippet: Fig. 5 FGF23 attenuates SDF-1-induced CXCR4 expression via interaction of FGF receptor-1 (FGFR1), but not Klotho. A FGFR-1, -2, -3, or -4 mRNA expression levels in EPCs were detected by RT-PCR. HK-2 lysates were used as positive controls. B EPCs were pre-treated with FGF23 and/or FGFR inhibitor (PD173074) for 30 min followed by SDF-1 stimulation for 15 min or 6 h. C EPCs harboring control or Klotho shRNA were pre-treated with FGF23 for 30 min followed by SDF-1 stimulation for 10 min or 6 h. D EPCs were pre-treated with Klotho neutralizing antibody for 60 min and FGF23 for 30 min followed by SDF-1 stimulation for 10 min or 24 h. E EPCs were treated with different doses of Klotho. F EPCs were collected at the indicated time points after Klotho treatment. G EPCs harboring control or Klotho shRNA were pre-treated with FGF23 for 24 h. Protein lysates were analyzed by immunoblot using indicated antibodies. β-actin or GAPDH were used as protein loading controls. The numbers under the gel lanes represent the relative protein level.

Article Snippet: For the Klotho knockdown assay, pGFP-C-shLenti vectors containing shRNA targeting human Klotho (TL303679A) or non-targeting scrambled shRNA cassette (TR30023) were purchased from Origene.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Control, shRNA, Western Blot

Journal: Archivum immunologiae et therapiae experimentalis

Article Title: A Comprehensive Study on the Anti-cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation.

doi: 10.1007/s00005-023-00669-w

Figure Lengend Snippet: Fig. 5 Analysis of epigenetic modulatory effect of querce- tin by a Human Telomerase enzyme (TE) ELISA. b Relative telomere length quantifica- tion of quercetin-treated and control, primary and metastasis colon cancer cells. The statisti- cal significance in the graph indicates *p < 0.05; **p < 0.01; ***p < 0.001

Article Snippet: Assessment of Human Klotho Protein Expression The human Klotho protein expression assay was performed using the human Klotho ELISA Kit (Elabscience, Cat No. E-EL-H5451) protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Control